Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavaud, Pernelle, Dumont, Clément, Thibault, Constance, Albiges, Laurence, Baciarello, Giulia, Colomba, Emeline, Flippot, Ronan, Fuerea, Alina, Loriot, Yohann, Fizazi, Karim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768840/
https://www.ncbi.nlm.nih.gov/pubmed/33488778
http://dx.doi.org/10.1177/1758835920978134
_version_ 1783629219925852160
author Lavaud, Pernelle
Dumont, Clément
Thibault, Constance
Albiges, Laurence
Baciarello, Giulia
Colomba, Emeline
Flippot, Ronan
Fuerea, Alina
Loriot, Yohann
Fizazi, Karim
author_facet Lavaud, Pernelle
Dumont, Clément
Thibault, Constance
Albiges, Laurence
Baciarello, Giulia
Colomba, Emeline
Flippot, Ronan
Fuerea, Alina
Loriot, Yohann
Fizazi, Karim
author_sort Lavaud, Pernelle
collection PubMed
description Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints.
format Online
Article
Text
id pubmed-7768840
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-77688402021-01-21 Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer Lavaud, Pernelle Dumont, Clément Thibault, Constance Albiges, Laurence Baciarello, Giulia Colomba, Emeline Flippot, Ronan Fuerea, Alina Loriot, Yohann Fizazi, Karim Ther Adv Med Oncol Review Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints. SAGE Publications 2020-12-23 /pmc/articles/PMC7768840/ /pubmed/33488778 http://dx.doi.org/10.1177/1758835920978134 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Lavaud, Pernelle
Dumont, Clément
Thibault, Constance
Albiges, Laurence
Baciarello, Giulia
Colomba, Emeline
Flippot, Ronan
Fuerea, Alina
Loriot, Yohann
Fizazi, Karim
Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
title Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
title_full Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
title_fullStr Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
title_full_unstemmed Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
title_short Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
title_sort next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768840/
https://www.ncbi.nlm.nih.gov/pubmed/33488778
http://dx.doi.org/10.1177/1758835920978134
work_keys_str_mv AT lavaudpernelle nextgenerationandrogenreceptorinhibitorsinnonmetastaticcastrationresistantprostatecancer
AT dumontclement nextgenerationandrogenreceptorinhibitorsinnonmetastaticcastrationresistantprostatecancer
AT thibaultconstance nextgenerationandrogenreceptorinhibitorsinnonmetastaticcastrationresistantprostatecancer
AT albigeslaurence nextgenerationandrogenreceptorinhibitorsinnonmetastaticcastrationresistantprostatecancer
AT baciarellogiulia nextgenerationandrogenreceptorinhibitorsinnonmetastaticcastrationresistantprostatecancer
AT colombaemeline nextgenerationandrogenreceptorinhibitorsinnonmetastaticcastrationresistantprostatecancer
AT flippotronan nextgenerationandrogenreceptorinhibitorsinnonmetastaticcastrationresistantprostatecancer
AT fuereaalina nextgenerationandrogenreceptorinhibitorsinnonmetastaticcastrationresistantprostatecancer
AT loriotyohann nextgenerationandrogenreceptorinhibitorsinnonmetastaticcastrationresistantprostatecancer
AT fizazikarim nextgenerationandrogenreceptorinhibitorsinnonmetastaticcastrationresistantprostatecancer

Ejemplares similares